December 06, 2017

First gastroenteropancreatic-neuroendocrine tumor (GEP-NET) patient in Europe for the COMPETE phase III clinical trial with n.c.a. 177Lu-Edotreotide (Solucin®)

First Patient enrolled in Europe for the clinical study COMPETE at the University Hospital Marburg, Germany. COMPETE to investigate a broad indication with non-functional GE-NET /functional or nonfunctional P-NET. Targeted...

Full releases >>

November 14, 2017

Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET

ITM’s subsidiary ITM Solucin lead 2-day-event focused on study update and efficient trial execution. Meeting attended by over 60 investigators as well as study nurses from 30 leading cancer centers in 10 countries.

Full releases >>

November 09, 2017

ITM as Front-Runner in the Life Sciences Industry of the Germany’s fastest growing Technology Companies

With a 174 % growth, ITM Isotopen Technologien München AG is one of the 50 winners of the Deloitte Technology Fast 50 Award 2017

Full releases >>

April 18, 2017

First Patient in Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced the enrollment of the first patient recruited in the COMPETE study, an international pivotal multi-center phase III clinical...

Full releases >>

August 04, 2016

ITM´s subsidiary ITG receives Drug Approval for EndolucinBeta®

ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope...

Full releases >>

May 10, 2016

EMA/CHMP adopts positive opinion for ITM’s EndolucinBeta®

ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive...

Full releases >>

March 24, 2016

ITM and Scil Proteins announce new Partnership for Targeted Radio Conjugates

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, and Scil Proteins, the expert company in affinity ligands and targeted carriers, today announced they have entered into a partnership covering...

Full releases >>